RecruitingNot ApplicableNCT07579286

Refusal of Sentinel Lymph Node Biopsy in Patients With Luminal A Subtype Early Breast Cancer

Sponsor

N.N. Petrov National Medical Research Center of Oncology

Enrollment

100 participants

Start Date

Jul 27, 2023

Study Type

INTERVENTIONAL

Conditions

Early Breast Cancer

Summary

Sentinel lymph node biopsy (SLNB) is the standard of axillary lymph node surgical staging in patients with early breast cancer. The main goal of the study is to abandon axillary surgery in patients over 59 years old with early, luminal A, clinical lymph node negative breast cancer.

Eligibility

Sex: FEMALEMin Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Breast resection with sentinel lymph node biopsy and a procedure called breast resection for people with early breast cancer. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREbreast resection

breast resection without sentinel lymph node biopsy, radiotherapy to the breast area and sentinel lymph nodes

PROCEDUREBreast resection with sentinel lymph node biopsy

Breast resection with sentinel lymph node biopsy, radiotherapy to the breast and axilla according to current treatment standards

Locations(1)

N.N. Petrov National Medical Research Center of Oncology

Saint Petersburg, Russian Federation, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07579286

Related Trials

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

NCT07106632105 locations

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

NCT075410791 location

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081229 locations

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

NCT066504231 location

Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers

NCT072339281 location